Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 505 participants.

Also called NCT02294474

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 505 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02294474
  • EudraCT 2014-002844-42
Other papers using this trial's data
  • Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study Diabetes technology & therapeutics, 2018-01 DOI, PubMed 29232162, PMC5770084 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Chile, Colombia, Germany, Hungary, Italy, Romania, Russia, South Korea, Spain, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02294474. Randomized; no masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2016-02 (actual). Results posted on 2018-01-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine
Acronym
SORELLA2
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
SAR342434
Intervention (Drug)
Humalog
Intervention (Drug)
insulin glargine HOE901
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct02294474
Content hash
0333e46947be2e07b3f34b8094d2e548152e0e589b3b1ec33187ad84d3ea7bc9